Welcome to our dedicated page for Arcturus Therape news (Ticker: ARCT), a resource for investors and traders seeking the latest updates and insights on Arcturus Therape stock.
Arcturus Therapeutics Holdings Inc. (NASDAQ: ARCT) is a San Diego-based commercial mRNA medicines and vaccines company focused on liver and respiratory rare disease therapeutics and infectious disease vaccines. News about Arcturus often centers on clinical trial progress, regulatory interactions and collaboration updates linked to its LUNAR® lipid-mediated delivery and STARR® self-amplifying mRNA (sa-mRNA) platforms.
Investors following ARCT news can expect regular updates on the companys RNA therapeutic candidates for ornithine transcarbamylase (OTC) deficiency and cystic fibrosis (CF), including interim data from Phase 1 and Phase 2 studies, safety and tolerability findings, biomarker changes and plans for longer-duration or pivotal trials. Disclosures have highlighted programs such as ARCT-032, an inhaled mRNA therapy for CF, and ARCT-810, an mRNA therapeutic candidate for OTC deficiency.
Arcturus also issues frequent announcements related to its infectious disease vaccine portfolio. These include developments for KOSTAIVE®, described as the first approved self-amplifying mRNA COVID-19 vaccine, along with sa-mRNA influenza candidates like ARCT-2138 and pandemic influenza A H5N1 candidate ARCT-2304. News items may cover Phase 1 or Phase 3 data, immunogenicity and safety results, and regulatory submissions or approvals in collaboration with CSL Seqirus and partners such as Meiji Seika Pharma.
Additional ARCT headlines often involve financial results, cash runway commentary, cost management actions, investor conference participation and SEC filings that provide corporate updates. Stock Titans ARCT news page aggregates these company press releases, regulatory disclosures and related coverage so readers can track how Arcturus clinical, regulatory and partnership milestones may influence sentiment around ARCT stock over time.
Arcturus Therapeutics Holdings Inc. (Nasdaq: ARCT), a clinical-stage mRNA medicines company, announced its participation in several upcoming investor and scientific conferences. Highlights include:
- Guggenheim Healthcare Talks: April 1, 2021, at 4:00 p.m. ET (Panel Discussion)
- 7th Annual Truist Securities Life Sciences Summit: May 4, 2021, at 1:50 p.m. ET (Fireside Chat)
- Genetic Vaccine Development Summit: May 20, 2021, at 1:30 p.m. ET (Presentation)
Details and presentation links are available on their website.
Arcturus Therapeutics Holdings Inc. (ARCT) reported its 2020 financial results, showing total revenues of $9.5 million, a significant decline from $20.8 million in 2019. The company incurred a net loss of $72.1 million for the year, compared to $26.0 million in the previous year. Despite this, Arcturus is advancing its ARCT-021 COVID-19 vaccine into Phase 3 trials and has received $46.6 million to support its vaccine stockpiling. The company expects its cash position of $463 million to sustain operations for over two years.
Arcturus Therapeutics Holdings Inc. (Nasdaq: ARCT) announced the acquisition of an exclusive license from Alexion Pharmaceuticals for patent-pending nucleic acid purification technologies. This strategic move aims to enhance the production efficiency of mRNA, critical for the development of vaccines and therapies. With this technology, Arcturus can scale up mRNA production while ensuring higher purity. This acquisition strengthens Arcturus' existing intellectual property portfolio, which is vital for its operations in RNA medicines and vaccines, including COVID-19 and Influenza.
Arcturus Therapeutics Holdings Inc. (Nasdaq: ARCT) will release its financial results for the quarter and year ended December 31, 2020, after market close on March 1, 2021. Following this announcement, a conference call and webcast will take place at 4:30 p.m. ET. Arcturus is focused on developing mRNA medicines and vaccines for infectious diseases, with products targeting COVID-19, Influenza, and rare liver and respiratory diseases. The company utilizes its proprietary LUNAR® and STARR™ technologies and is supported by a strong patent portfolio and various collaborations.
Arcturus Therapeutics Holdings Inc. (Nasdaq: ARCT), a clinical-stage mRNA medicines company, announced its participation in several upcoming investor conferences. Notable events include:
- BIO CEO & Investor Digital Conference: February 12, 2021, at 12:00 p.m. ET
- Raymond James Annual Institutional Investors Conference: March 3, 2021, at 11:40 a.m. ET
- H.C. Wainwright Global Life Sciences Conference: March 9, 2021, at 7:00 a.m. ET
- Barclays Global Healthcare Conference: March 10, 2021, at 1:50 p.m. ET
Arcturus focuses on developing vaccines and treatments for infectious diseases.
Arcturus Therapeutics Holdings Inc. (Nasdaq: ARCT) will engage in a panel discussion at the 13th Annual Biotech Showcase™ Investor Conference.
The discussion, titled COVID-19 Vaccines: All things impacted by COVID-19, will occur on January 11, 2020, at 1:00 p.m. ET. The event can be accessed on-demand from January 12 to March 31, 2020, via the event platform.
Arcturus specializes in mRNA medicines, with a diverse pipeline addressing COVID-19, Influenza, and rare diseases.
Arcturus Therapeutics has received FDA allowance for its IND application regarding the Phase 2 clinical study of its vaccine candidate ARCT-021, based on preceding favorable data from the Phase 1/2 study. The Phase 2 trial will involve 600 participants, evaluating both safety and immunogenicity. The aim is to inform dosing for a prospective Phase 3 study planned for Q2 2021, pending successful results. The ARCT-021 vaccine shows promise for a differentiated profile and may potentially require only a single dose for adequate protection against SARS-CoV-2.
Arcturus Therapeutics Holdings Inc. (Nasdaq: ARCT) has selected ARCT-032, an aerosolized mRNA therapeutic candidate, for Cystic Fibrosis (CF) treatment. This candidate aims to express functional CFTR protein in the lungs, addressing the root cause of CF lung disease. The development is backed by preclinical data showing potential to restore CFTR activity in affected models. The company emphasizes ARCT-032's capability to benefit all CF patients, regardless of genetic mutations, enhancing existing treatment options.
Arcturus Therapeutics Holdings announced approval from the Singapore Health Sciences Authority to conduct a Phase 2 clinical study for its COVID-19 vaccine candidate, ARCT-021. This follows promising results from the Phase 1/2 trial, which demonstrated a robust immune response in all participants. The Phase 2 study aims to identify the best vaccination regimen ahead of a global Phase 3 study anticipated in Q2 2021. Preliminary preclinical data indicated significant protection from SARS-CoV-2 in animal models, further supporting the candidate's potential efficacy.
Arcturus Therapeutics Holdings Inc. (NASDAQ: ARCT) has announced a public offering of 1,365,000 shares priced at $110.00 each, aiming for approximately $150 million in gross proceeds. The offering includes a 30-day option for underwriters to purchase an additional 204,750 shares. The funds are designated for clinical trials and manufacturing its LUNAR-COV19 vaccine. The offering is underpinned by a registration statement filed with the SEC, with closing anticipated around December 10, 2020.